– Reports Promising Early Data from Lead Clinical Program, JK07, for the Treatment of Heart Failure with Reduced Ejection Fraction – – Initiates Enrollment in Second Cohort of JK07 Phase 1 Dose Escalation Study – GAITHERSBURG, Md.–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel […]